Scarica l'app Stockscreener
8.69
6.96%
-0.65
Dopo l'orario di chiusura:
8.74
0.05
+0.58%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VIR Giù?
Forum
Previsione
Precedente Chiudi:
$9.34
Aprire:
$9
Volume 24 ore:
2.15M
Relative Volume:
1.17
Capitalizzazione di mercato:
$1.47B
Reddito:
$68.56M
Utile/perdita netta:
$-437.99M
Rapporto P/E:
-2.7466
EPS:
-3.1639
Flusso di cassa netto:
$-396.61M
1 W Prestazione:
-7.85%
1M Prestazione:
-12.66%
6M Prestazione:
+14.95%
1 anno Prestazione:
+50.87%
Intervallo 1D:
$8.62
$9.15
Intervallo di 1 settimana:
$8.62
$9.59
Portata 52W:
$4.155
$11.66
Vir Biotechnology Inc Stock (VIR) Company Profile
Nome
Vir Biotechnology Inc
Settore
Industria
Telefono
415-906-4324
Indirizzo
1800 OWENS STREET, SAN FRANCISCO, CA
Compare VIR vs VRTX, REGN, ARGX, RVMD, ALNY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VIR
Vir Biotechnology Inc
|
8.69 | 1.47B | 68.56M | -437.99M | -396.61M | -3.1639 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-24 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2025-09-03 | Iniziato | Evercore ISI | Outperform |
| 2025-08-27 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-01-29 | Downgrade | JP Morgan | Overweight → Neutral |
| 2023-09-08 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-03-06 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-02-21 | Aggiornamento | Goldman | Neutral → Buy |
| 2023-01-27 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-09-14 | Iniziato | SVB Leerink | Outperform |
| 2022-09-09 | Iniziato | Morgan Stanley | Underweight |
| 2022-03-03 | Aggiornamento | Robert W. Baird | Underperform → Neutral |
| 2021-12-21 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2021-10-25 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2021-09-22 | Downgrade | Goldman | Buy → Neutral |
| 2021-06-04 | Ripresa | Robert W. Baird | Neutral |
| 2021-01-27 | Downgrade | JP Morgan | Neutral → Underweight |
| 2021-01-20 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-05 | Iniziato | BofA Securities | Buy |
| 2020-09-14 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-09-11 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2020-08-20 | Iniziato | Needham | Buy |
| 2020-03-19 | Downgrade | JP Morgan | Neutral → Underweight |
| 2020-03-13 | Downgrade | Goldman | Buy → Neutral |
| 2020-02-27 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2020-02-04 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-11-14 | Iniziato | Robert W. Baird | Neutral |
| 2019-11-05 | Iniziato | Barclays | Overweight |
| 2019-11-05 | Iniziato | Cowen | Outperform |
| 2019-11-05 | Iniziato | Goldman | Buy |
| 2019-11-05 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Vir Biotechnology Inc Borsa (VIR) Ultime notizie
Vir Biotechnology, Inc. Revenue Breakdown – NASDAQ:VIR - TradingView
Vir Biotechnology Appoints Brent Sabatini as Interim Principal Financial Officer - Moomoo
Vir Biotechnology, Inc. (VIR) Q4 2023 Earnings ReportResults, Call & Slides - TipRanks
Vir Biotechnology Names Brent Sabatini Interim Finance Chief - The Globe and Mail
Vir Biotechnology, Inc. (VIR) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
TradingKey - TradingKey
Vir Biotechnology, Inc. (VIR) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
VIR|Vir Biotechnology Inc|Price:8.690|Chg%:-0.650 - TradingKey
Vir Biotechnology, Inc. (VIR) Q1 2026 Earnings ReportResults, Call & Slides - TipRanks
Vir Biotechnology Inc (VIR) Institutional Confidence - TradingKey
Vir Biotechnology Inc (VIR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Vir Biotechnology Inc (VIR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Vir Biotechnology Inc (VIR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Vir Biotechnology Inc (VIR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Vir Biotechnology Inc (VIR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Vir Biotechnology Inc (VIR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Vir Biotechnology Inc (VIR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Vir Biotechnology Inc (VIR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Vir Biotechnology (VIR) Appoints Interim Financial Officer Amid Leadership Changes - GuruFocus
Vir Biotechnology: Sabatini Has Served as Senior Vice Pres and Chief Acctg Officer Since Feb 2023 >VIR - Moomoo
Why is Vir Biotechnology stock sliding today? - Investing.com
Why is Vir Biotechnology stock sliding today? By Investing.com - Investing.com Canada
Vir Biotechnology (VIR) Announces New Interim Financial Leadersh - GuruFocus
Vir Biotechnology (NASDAQ:VIR) Shares Gap DownWhat's Next? - MarketBeat
Vir Biotechnology stock falls as CFO O’Byrne departs By Investing.com - Investing.com India
Vir Biotechnology stock falls as CFO O’Byrne departs - Investing.com
Vir Biotechnology Announces Chief Financial Officer Transition - BioSpace
Vir Biotechnology, Inc. Announces Resignation of Jason O'Byrne as Executive Vice President, Effective August 3, 2026 - marketscreener.com
Vir Biotechnology Appoints Brent Sabatini as Interim CFO Following Jason O'Byrne's Resignation - Kalkine Media
Vir Biotechnology names interim finance chief - Investing.com
Vir Biotechnology (VIR) TD Cowen 46th Annual Health Care Conference Summary - Quartr
Vir Biotechnology names interim finance chief By Investing.com - Investing.com Canada
VIR Q2'26 Earnings: revenue estimate is 135.88M USD - TradingView
VIR|Vir Biotechnology Inc|Price:8.675|Chg%:-0.665 - TradingKey
Vir Biotechnology to Host Conference Call for Second Quarter 2026 Financial Results - BioSpace
Vir Biotechnology to host conference call for Q2 2026 results - scanx.trade
VIR Stock Surges 60% Pre-Market Today – Analysts Cheer Strong Cancer Data, Astellas Partnership - Stocktwits
Vir Biotechnology, Inc. (NASDAQ:VIR) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Vir Biotechnology (VIR) Bank of America Global Healthcare Conference 2026 Summary - Quartr
VIR stock reacts to latest clinical updates and cash position - Ad-hoc-news.de
Why Did Vir Biotechnology Stock Surge 60% After-Hours Today? - Stocktwits
Vir Biotechnology nears key trial results in he... - Pluang
Vir Biotechnology: Multiple Catalysts In Hepatitis And Oncology Ahead (NASDAQ:VIR) - Seeking Alpha
Hillsdale Investment Management Inc. Invests $1.44 Million in Vir Biotechnology, Inc. $VIR - MarketBeat
Discipline and Rules-Based Execution in VIR Response - Stock Traders Daily
Vir Biotechnology, Inc. $VIR Shares Bought by Candriam S.C.A. - MarketBeat
Y Intercept Hong Kong Ltd Takes Position in Vir Biotechnology, Inc. $VIR - MarketBeat
Vir Biotechnology (VIR) BofA Securities 2025 Healthcare Conference Summary - Quartr
Will Vir Biotechnology (NASDAQ:VIR) Spend Its Cash Wisely? - Moomoo
A Quick Look at Today's Ratings for Vir Biotechnology(VIR.US), With a Forecast Between $16 to $30 - Moomoo
Vir Biotechnology, Inc. $VIR Stock Holdings Increased by Pictet Asset Management Holding SA - MarketBeat
Vir Biotechnology Inc Azioni (VIR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.46%
0.84%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):